recombinant adenovirus-p53 SCH-58500
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fallopian Tube Cancer
Conditions
Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Trial Timeline
Jun 1, 1999 → Jul 1, 2000
NCT ID
NCT00002960About recombinant adenovirus-p53 SCH-58500
recombinant adenovirus-p53 SCH-58500 is a phase 1 stage product being developed by Merck for Fallopian Tube Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00002960. Target conditions include Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer.
What happened to similar drugs?
0 of 4 similar drugs in Fallopian Tube Cancer were approved
Approved (0) Terminated (2) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002960 | Phase 1 | Completed |
Competing Products
20 competing products in Fallopian Tube Cancer